Transient expression of VP2 in Nicotiana benthamiana and its use as a plant-based vaccine against Infectious Bursal Disease Virus

Gómez, Emma Laura Alfaro; Lucero, María Soledad; Zoth, Silvina Andrea Chimeno; Carballeda, Juan Manuel; Gravisaco, Marí­a José; Berinstein, Analía

doi:10.1016/j.vaccine.2013.03.064

Cited by 44 publications

(27 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples were obtained weekly after immunization to analyze the induced specific humoral response. After 7 weeks, chickens were orally challenged with 2×10 3 Tissue Culture Infectious Dose 50 (TCID 50 ) of the IBDV LZD strain as previously described (Gómez et al, 2013). Five days later, the birds were sacrificed, and bursae were removed for analysis of protection parameters.…”

Section: Recombinant Canarypox Virus Expressing the Vp2 Protein Of Inmentioning

confidence: 99%

Recombinant canarypox virus expressing the VP2 protein of infectious bursal disease virus induces protection in vaccinated SPF chickens

et al. 2016

View full text Add to dashboard Cite

Section: Recombinant Canarypox Virus Expressing the Vp2 Protein Of Inmentioning

confidence: 99%

Recombinant canarypox virus expressing the VP2 protein of infectious bursal disease virus induces protection in vaccinated SPF chickens

et al. 2016

View full text Add to dashboard Cite

“…The VP2 protein of IBDV was previously expressed in rice seed and detected as a 50 kDa product [47]. Previous study also reported on identification of VP2 protein of approximately 50 kDa expressed in N. benthamiana via agroinfiltration approach [48].…”

Section: Discussionmentioning

confidence: 98%

Single Nucleotide Modification of VP2 Gene of Highly Virulent Infectious Bursal Disease Virus for Effective Expression Strategy in Tobacco

Siti-Hasmah¹

2017

OAJMB

View full text Add to dashboard Cite

show abstract

“…Infectious bronchitis virus (IBV) S1 glycoprotein was expressed in potato, and in another study VP2 protein of infectious bursal disease virus (IBDV) was expressed in rice seeds, were used to immunize the chicken orally and was found equally protective as a commercial vaccine [78]. However, transiently expressed VP2 antigen in Nicotiana benthamiana also induced neutralizing antibodies in chickens [79]. Expression of the recombinant hemagglutininneuraminidase coat protein of Newcastle disease virus in tobacco suspension culture and their injectable vaccine got USFDA approval in 2006 [80].…”

Section: Poultrymentioning

confidence: 99%

Recombinant Plant Engineering for Immunotherapeutic Production

et al. 2017

View full text Add to dashboard Cite

Purpose of Review The requirement for large quantities of therapeutic proteins has fueled a great interest in the production of recombinant proteins in plant bioreactors. The vaccines and bio-therapeutic protein production in plants hold the promise of significantly lowering the cost of manufacturing life-saving drugs. This review will reflect the current status and challenges that the molecular farming platform faces becoming a strategic solution for the development of low-cost bio-therapeutics for developing countries. Recent Findings Different plant parts have been successfully identified as suitable expression systems for the commercial production of therapeutic proteins for some human and animal diseases ranging from common cold to AIDS. The processed therapeutics from such sources are devoid of any toxic components. The large-scale cultivation of these transgenic plants would be possible anywhere in the world including developing countries, which lack sophisticated drug manufacturing units. A couple of such commercially generated products have already hit the market with success. Newer methods using suitable plant viruses and recombinant gene expression systems have already been devised for producing therapeutic proteins and peptides. Summary Plants are promising bio-factories for therapeutic protein production because of their several advantages over the other expression systems especially the advanced mechanisms for protein synthesis and post-translational modification which are very much similar to animal cells. Plant biotechnologists are much attracted to the bio-farming because of its flexibility, scalability, low manufacturing cost, as well as the lack of risk of toxic or pathogenic contamination. A number of projects on bio-farming are designed and are at various developmental stages but have not yet become available to the pharmaceutical industry. Therefore, we need further advancement in the optimization of lab protocols for up-scaling the production of such therapeutics at commercial level with a promise to offer their best clinical use.

show abstract

Transient expression of VP2 in Nicotiana benthamiana and its use as a plant-based vaccine against Infectious Bursal Disease Virus

Cited by 44 publications

References 41 publications

Recombinant canarypox virus expressing the VP2 protein of infectious bursal disease virus induces protection in vaccinated SPF chickens

Recombinant canarypox virus expressing the VP2 protein of infectious bursal disease virus induces protection in vaccinated SPF chickens

Single Nucleotide Modification of VP2 Gene of Highly Virulent Infectious Bursal Disease Virus for Effective Expression Strategy in Tobacco

Recombinant Plant Engineering for Immunotherapeutic Production

Contact Info

Product

Resources

About